FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)
The FDA has approved a supplemental application for SARCLISA, a monoclonal antibody targeting CD38.
Asset / Drug
Drug and asset intelligence for SARCLISA with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Monoclonal Antibody
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.